Roivant Sciences Overview April 2024

Roivant Sciences presents its April 2024 corporate overview highlighting its platform for developing transformative medicines. The company demonstrates a proven track record with 10 consecutive positive Phase 3 trials and 6 FDA approvals, featuring product candidates including VTAMA, IMVT-1402, and brepocitinib. With $6.7 billion in consolidated cash as of December 31, 2023, Roivant is positioned to expand its pipeline and pursue strategic capital allocation.